<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146178">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750086</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001956</org_study_id>
    <nct_id>NCT01750086</nct_id>
  </id_info>
  <brief_title>Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption</brief_title>
  <official_title>Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis
      medications when combined with teriparatide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bone turnover marker (blood sample)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab 60mg subcutaneous injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate 70mg weekly x 8 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide 40-mcg subcutaneous injection</intervention_name>
    <arm_group_label>Denosumab 60mg subcutaneous injection</arm_group_label>
    <arm_group_label>Alendronate 70mg weekly x 8 weeks</arm_group_label>
    <other_name>Forteo速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Must satisfy A and B and C below:

        A. Women aged 45+

        B. Postmenopausal

        C. Osteoporotic with high risk of fracture

        Exclusion Criteria:

          -  History of significant hepatic, renal, cardiovascular, malignant disease, or
             conditions with impaired immune system

          -  Current alcohol or substance abuse

          -  Major psychiatric disorders

          -  Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia

          -  Known congenital or acquired bone disease other than osteoporosis

          -  Current use or past use in the past 12 months of oral bisphosphonates

          -  Current use or use in the past 3 months of estrogens, selective estrogen receptor
             modulators, or calcitonin

          -  Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months

          -  Any current or previous use of strontium or intravenous bisphosphonates

          -  Sensitivity to cell-derived drug products or teriparatide

          -  Extensive dental work involving dental extraction or dental implant within the past 2
             months or in the upcoming 2 months

          -  Inability to sit upright for 30 minutes

          -  Esophageal abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Z Leder, MD</last_name>
    <phone>617-724-2039</phone>
    <email>bzleder@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joy N Tsai, MD</last_name>
    <phone>617-726-4650</phone>
    <email>jntsai@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Tsai, MD</last_name>
      <phone>617-726-4650</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Z Leder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cosman F, Eriksen EF, Recknor C, Miller PD, Gua単abens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.</citation>
    <PMID>20814967</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26. Epub 2003 Sep 20.</citation>
    <PMID>14500805</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug 11;353(6):566-75.</citation>
    <PMID>16093465</PMID>
  </reference>
  <reference>
    <citation>Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001 Oct;142(10):4295-304.</citation>
    <PMID>11564687</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45. doi: 10.1210/jc.2009-1703. Epub 2010 Feb 17.</citation>
    <PMID>20164296</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>teriparatide</keyword>
  <keyword>alendronate</keyword>
  <keyword>Forteo速</keyword>
  <keyword>Prolia速</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Resorption</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
